Pharmiva AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHARM.ST research report →
Companywww.pharmiva.com
Pharmiva AB (publ) engages in the research and development of medical products. The company develops Vernivia, an over-the-counter vaginal mousse for the treatment of bacterial vaginosis. The company is based in Lund, Sweden.
- CEO
- Anna Linton
- IPO
- 2021
- Employees
- 5
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $12.93M
- P/E
- -0.41
- P/S
- 4.92
- P/B
- 0.36
- EV/EBITDA
- 0.05
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.40%
- Op Margin
- -900.61%
- Net Margin
- -900.91%
- ROE
- -82.12%
- ROIC
- -88.20%
Growth & Income
- Revenue
- $2.63M · 959.68%
- Net Income
- $-23,676,000 · -14.02%
- EPS
- $-1.36 · 51.43%
- Op Income
- $-23,668,000
- FCF YoY
- -3.11%
Performance & Tape
- 52W High
- $2.32
- 52W Low
- $0.56
- 50D MA
- $0.80
- 200D MA
- $1.12
- Beta
- 1.56
- Avg Volume
- 19.58K
Get TickerSpark's AI analysis on PHARM.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PHARM.ST Coverage
We haven't published any research on PHARM.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PHARM.ST Report →